tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Aug 11;10(8):1297.
doi: 10.3390/vaccines10081297.
Psychological and Psychiatric Events Following Immunization with Five Different Vaccines against SARS-CoV-2
Mario García-Alanis[SUP] 1 [/SUP], Marisa Morales-Cárdenas[SUP] 1 [/SUP], Liz Nicole Toapanta-Yanchapaxi[SUP] 1 [/SUP], Erwin Chiquete[SUP] 1 [/SUP], Isaac Núñez[SUP] 2 [/SUP], Santa Elizabeth Ceballos-Liceaga[SUP] 3 [/SUP], Guillermo Carbajal-Sandoval[SUP] 3 [/SUP], Carla Toledo-Salinas[SUP] 4 [/SUP], David Alejandro Mendoza-Hernández[SUP] 5 [/SUP], Selma Cecilia Scheffler-Mendoza[SUP] 5 [/SUP], José Antonio Ortega-Martell[SUP] 6 [/SUP], Daniel Armando Carrillo-García[SUP] 3 [/SUP], Noé Hernández-Valdivia[SUP] 3 [/SUP], Alonso Gutiérrez-Romero[SUP] 7 [/SUP], Javier Andrés Galnares-Olalde[SUP] 7 [/SUP], Fernando Daniel Flores-Silva[SUP] 1 [/SUP], José Luis Díaz-Ortega[SUP] 8 [/SUP], Gustavo Reyes-Terán[SUP] 4 [/SUP], Hugo López-Gatell[SUP] 9 [/SUP], Ricardo Cortes-Alcalá[SUP] 9 [/SUP], José Rogelio Pérez-Padilla[SUP] 10 [/SUP], Antonio Arauz[SUP] 7 [/SUP], Miguel García-Grimshaw[SUP] 1 11 [/SUP], Sergio Iván Valdés-Ferrer[SUP] 1 12 13 [/SUP]
Affiliations
Abstract
Background: Despite the high number of vaccines administered against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, the information on the psychological/psychiatric adverse events following immunization (AEFI) with these newly developed vaccines remains scarce.
Objective: To describe the frequency of psychological/psychiatric symptoms among recipients of five different anti-SARS-CoV-2 vaccines and to explore the factors associated with their development reported in the nationwide Mexican registry of AEFI against SARS-CoV-2.
Methods: Descriptive study of all the psychological/psychiatric symptoms, including anxiety, panic attacks, insomnia, and agitation reported to the Mexican Epidemiological Surveillance System from 21 December 2020 to 27 April 2021, among adult (≥18 years old) recipients of 7,812,845 doses of BNT162b2, ChAdOx1 nCov-19, rAd26-rAd5, Ad5-nCoV, or CoronaVac. The factors associated with their development are determined by multivariate regression analysis.
Results: There were 19,163 AEFI reports during the study period; amongst them, 191 (1%) patients had psychological/psychiatric symptoms (median age of 41 years, interquartile range of 32-54; 149 [78%] women) for an observed incidence of 2.44 cases per 100,000 administered doses (95% confidence interval [CI] 2.12-2.82), 72.8% of psychiatric AEFIs were reported among recipients of BNT162b2. The median time from vaccination to symptom onset was 35 min (interquartile range: 10-720). Overall, the most common psychological/psychiatric symptoms were anxiety in 129 (67.5%) patients, panic attacks in 30 (15.7%), insomnia in 25 (13%), and agitation in 11 (5.7%). After adjusting for the confounding factors, the odds for developing psychological/psychiatric symptoms were higher for those concurrently reporting syncope (odds ratio [OR]: 4.73, 95% CI: 1.68-13.33); palpitations (OR: 2.47, 95% CI: 1.65-3.70), and dizziness (OR: 1.59, 95% CI: 1.10-2.28).
Conclusion: In our population, psychological/psychiatric symptoms were extremely infrequent AEFIs. No severe psychiatric AEFIs were reported. Immunization stress-related responses might explain most of the detected cases.
Keywords: SARS-CoV-2; anxiety; fear; immunization stress-related responses; panic attack; vaccines.
. 2022 Aug 11;10(8):1297.
doi: 10.3390/vaccines10081297.
Psychological and Psychiatric Events Following Immunization with Five Different Vaccines against SARS-CoV-2
Mario García-Alanis[SUP] 1 [/SUP], Marisa Morales-Cárdenas[SUP] 1 [/SUP], Liz Nicole Toapanta-Yanchapaxi[SUP] 1 [/SUP], Erwin Chiquete[SUP] 1 [/SUP], Isaac Núñez[SUP] 2 [/SUP], Santa Elizabeth Ceballos-Liceaga[SUP] 3 [/SUP], Guillermo Carbajal-Sandoval[SUP] 3 [/SUP], Carla Toledo-Salinas[SUP] 4 [/SUP], David Alejandro Mendoza-Hernández[SUP] 5 [/SUP], Selma Cecilia Scheffler-Mendoza[SUP] 5 [/SUP], José Antonio Ortega-Martell[SUP] 6 [/SUP], Daniel Armando Carrillo-García[SUP] 3 [/SUP], Noé Hernández-Valdivia[SUP] 3 [/SUP], Alonso Gutiérrez-Romero[SUP] 7 [/SUP], Javier Andrés Galnares-Olalde[SUP] 7 [/SUP], Fernando Daniel Flores-Silva[SUP] 1 [/SUP], José Luis Díaz-Ortega[SUP] 8 [/SUP], Gustavo Reyes-Terán[SUP] 4 [/SUP], Hugo López-Gatell[SUP] 9 [/SUP], Ricardo Cortes-Alcalá[SUP] 9 [/SUP], José Rogelio Pérez-Padilla[SUP] 10 [/SUP], Antonio Arauz[SUP] 7 [/SUP], Miguel García-Grimshaw[SUP] 1 11 [/SUP], Sergio Iván Valdés-Ferrer[SUP] 1 12 13 [/SUP]
Affiliations
- PMID: 36016185
- DOI: 10.3390/vaccines10081297
Abstract
Background: Despite the high number of vaccines administered against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, the information on the psychological/psychiatric adverse events following immunization (AEFI) with these newly developed vaccines remains scarce.
Objective: To describe the frequency of psychological/psychiatric symptoms among recipients of five different anti-SARS-CoV-2 vaccines and to explore the factors associated with their development reported in the nationwide Mexican registry of AEFI against SARS-CoV-2.
Methods: Descriptive study of all the psychological/psychiatric symptoms, including anxiety, panic attacks, insomnia, and agitation reported to the Mexican Epidemiological Surveillance System from 21 December 2020 to 27 April 2021, among adult (≥18 years old) recipients of 7,812,845 doses of BNT162b2, ChAdOx1 nCov-19, rAd26-rAd5, Ad5-nCoV, or CoronaVac. The factors associated with their development are determined by multivariate regression analysis.
Results: There were 19,163 AEFI reports during the study period; amongst them, 191 (1%) patients had psychological/psychiatric symptoms (median age of 41 years, interquartile range of 32-54; 149 [78%] women) for an observed incidence of 2.44 cases per 100,000 administered doses (95% confidence interval [CI] 2.12-2.82), 72.8% of psychiatric AEFIs were reported among recipients of BNT162b2. The median time from vaccination to symptom onset was 35 min (interquartile range: 10-720). Overall, the most common psychological/psychiatric symptoms were anxiety in 129 (67.5%) patients, panic attacks in 30 (15.7%), insomnia in 25 (13%), and agitation in 11 (5.7%). After adjusting for the confounding factors, the odds for developing psychological/psychiatric symptoms were higher for those concurrently reporting syncope (odds ratio [OR]: 4.73, 95% CI: 1.68-13.33); palpitations (OR: 2.47, 95% CI: 1.65-3.70), and dizziness (OR: 1.59, 95% CI: 1.10-2.28).
Conclusion: In our population, psychological/psychiatric symptoms were extremely infrequent AEFIs. No severe psychiatric AEFIs were reported. Immunization stress-related responses might explain most of the detected cases.
Keywords: SARS-CoV-2; anxiety; fear; immunization stress-related responses; panic attack; vaccines.